Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to read, sign and date the informed consent and HIPAA documents~* Willing and able to comply with all study procedures~* Be at least 18 years of age~* Patient-reported history of dry eye in both eyes~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~* Artificial tear use within the past 30 days~Exclusion Criteria:~* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy~* Unwilling to avoid wearing contact lenses for 7 days prior to first visit and for the duration of the study~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.~* Use of any prohibited medications at any time during the study unless otherwise specified~* Any significant illness that could interfere with study parameters~* History of laser assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to first visit, and/or any other ocular surgical procedure within 12 months prior to first visit; or any scheduled ocular surgical procedure during the study period.~* Known history of alcohol and/or drug abuse~* Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lifitegrast (Type: EXPERIMENTAL): Lifitegrast Ophthalmic Solution (5.0%)
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).